Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.

Br J Cancer · 2019 · PMC6738100 · PMID 31239542

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

did not reach statistical significancep = 0.10so close (0.05 < p ≤ 0.1)

There was a trend towards delayed tumour regrowth with adjuvant plerixafor for 3 weeks compared to continuous plerixafor for 6 weeks (3 weeks during RTCT and 3 weeks after RTCT) (median regrowth time 27.5 weeks), although this did not reach statistical significance ( p = 0.10).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.